+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Skin Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5319139
  • Report
  • April 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • AB Sciences
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • iCAD Inc
  • Mylan N.V
  • Roche
  • MORE
Skin Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global skin cancer drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the skin cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Skin Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:
1) By Type: Actinic Keratoses (AK); Basal cell carcinoma (BCC); Squamous cell carcinoma (SCC); Melanoma
2) By End Users: Hospitals; Cancer Research Centers; Clinics
3) By Drug Class: Chemotherapy; Immunotherapy; Targeted Agents & Other Drugs

Companies Mentioned: Novartis AG; Bristol Myers Squibb; Eli Lilly; Meda; Sun Pharmaceutical Industries Ltd

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Sciences
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • iCAD Inc
  • Mylan N.V
  • Roche
  • MORE
1. Executive Summary

2. Skin Cancer Drugs Market Characteristics

3. Skin Cancer Drugs Market Trends And Strategies

4. Impact Of COVID-19 on Skin Cancer Drugs

5. Skin Cancer Drugs Market Size And Growth
5.1. Global Skin Cancer Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Skin Cancer Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market

6. Skin Cancer Drugs Market Segmentation
6.1. Global Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Actinic Keratoses (AK)
  • Basal cell carcinoma (BCC)
  • Squamous cell carcinoma (SCC)
  • Melanoma
6.2. Global Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospitals
  • Cancer Research Centers
  • Clinics
6.3. Global Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Chemotherapy
  • Immunotherapy
  • Targeted Agents & Other Drugs
7. Skin Cancer Drugs Market Regional And Country Analysis
7.1. Global Skin Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Skin Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Skin Cancer Drugs Market
8.1. Asia-Pacific Skin Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.4. Asia-Pacific Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Skin Cancer Drugs Market
9.1. China Skin Cancer Drugs Market Overview
9.2. China Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.4. China Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Skin Cancer Drugs Market
10.1. India Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.3. India Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Skin Cancer Drugs Market
11.1. Japan Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.3. Japan Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Skin Cancer Drugs Market
12.1. Australia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.3. Australia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Skin Cancer Drugs Market
13.1. Indonesia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.3. Indonesia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Skin Cancer Drugs Market
14.1. South Korea Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.3. South Korea Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Skin Cancer Drugs Market
15.1. Western Europe Skin Cancer Drugs Market Overview
15.2. Western Europe Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.4. Western Europe Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Skin Cancer Drugs Market
16.1. UK Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.3. UK Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Skin Cancer Drugs Market
17.1. Germany Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.3. Germany Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Skin Cancer Drugs Market
18.5. France Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.6. France Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.7. France Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Skin Cancer Drugs Market
19.1. Eastern Europe Skin Cancer Drugs Market Overview
19.2. Eastern Europe Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.4. Eastern Europe Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Skin Cancer Drugs Market
20.1. Russia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.3. Russia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Skin Cancer Drugs Market
21.1. North America Skin Cancer Drugs Market Overview
21.2. North America Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.4. North America Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Skin Cancer Drugs Market
22.1. USA Skin Cancer Drugs Market Overview
22.2. USA Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.4. USA Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Skin Cancer Drugs Market
23.1. South America Skin Cancer Drugs Market Overview
23.2. South America Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.4. South America Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Skin Cancer Drugs Market
24.1. Brazil Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.3. Brazil Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Skin Cancer Drugs Market
25.1. Middle East Skin Cancer Drugs Market Overview
25.2. Middle East Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.4. Middle East Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Skin Cancer Drugs Market
26.1. Africa Skin Cancer Drugs Market Overview
26.2. Africa Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.4. Africa Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Skin Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Skin Cancer Drugs Market Competitive Landscape
27.2. Skin Cancer Drugs Market Company Profiles
27.2.1. Novartis AG
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Bristol Myers Squibb
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Eli Lilly
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Meda
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Sun Pharmaceutical Industries Ltd
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Skin Cancer Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Skin Cancer Drugs Market

30. Skin Cancer Drugs Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Sciences
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • iCAD Inc
  • Mylan N.V
  • Roche
  • MORE
Major players in the global skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, and Sun Pharmaceutical Industries Ltd.

The global skin cancer drugs market is expected to grow from $1.44 billion in 2020 to $1.61 billion in 2021 at a compound annual growth rate (CAGR) of 11.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.72 billion in 2025 at a CAGR of 14%.

The skin cancer drugs market consists of sales of skin cancer drugs. Skin Cancer is an unrestricted growth of abnormal skin cells that lead skin cells to proliferate rapidly and form malignant tumors. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma or melanoma. Examples of skin cancer drug include 5-FU, Aldara and Efudex.

In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. This acquisition would help Bristol-Myers Squibb to widen its portfolio of drug in skin cancer market. This acquisition would also help Bristol-Myers Squibb to expedite the development of new innovative drugs which are in the early stages of drug pipeline. Celgene is an innovative biotechnology company that manufactures and develops cancer drugs. Celgene was founded in 1986 and is headquartered at Summit, New Jersey, United States.

The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. The manufacturers of skin cancer drugs and all other drugs need to comply with manufacturing practices specified by the EMA. EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. EMA also educates the patients regarding the risks associated in taking skin cancer drugs such as Tafinlar and Opdivo, what are the safety measures that are needed to be taken while consuming the drug, benefits of the drug and all other relevant information pertaining to such drugs.

Significant rise in prevalence of skin cancer is driving the demand for the drugs for Skin Cancer. To treat such high cases of skin cancer, more number of new innovative skin cancer drugs is being manufactured. According to the American Academy Of Dermatology, 192,310 new cases of Melanoma type skin cancer were expected in 2019. Additionally, non-invasive type skin cancer count could rise to 95,830 and 96,480 invasive skin cancer could be diagnosed in US in 2019. According to the American Academy Of Dermatology, each year roughly around 3 million Americans get diagnosed by skin cancer. This is boosting the demand for skin cancer drugs and thus driving the market.

Increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs targets melanoma cells only. The chemical drugs attack any fast dividing cells while targeted therapies only attack the skin cancer causing melanoma cells. Thus, doctors are preferring targeted therapies to treat skin cancer. This is expected to affect the sales of conventional chemical skin cancer drugs and limit the growth of the market going forward.

Companies in the Skin Cancer Market are increasingly looking for Strategic Alliances with other companies in the market. Strategic Alliance would help companies to enhance their R&D capability, expedite the development process of new drugs and reinforce competitive position in the market. For example Leo Pharma has formed a strategic alliance with PellePharm in 2018, to develop a drug to treat a very rare form of skin cancer called Gorlin syndrome. MorphoSys and LEO Pharma strategically worked together to develop antibodies pertaining to the treatment of skin cancer. Pfizer had entered into a strategic alliance with Merck KGaA to manufacture an innovative drug pertaining to skin cancer.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Novartis AG
  • Bristol Myers Squibb
  • Eli Lilly
  • Meda
  • Sun Pharmaceutical Industries Ltd
  • Roche
  • Aqua Pharmaceuticals
  • Bausch Health
  • GlaxoSmithKline PLC
  • Pfizer Inc
  • AstraZeneca
  • Sanofi SA
  • Qiagen
  • Boehringer Ingelheim
  • Elekta AB
  • Varian Medical Systems
  • Valeant Pharmaceuticals
  • Mylan N.V
  • Merck & Co
  • Cannabis Science Inc
  • Cellceutix Corp
  • LEO Pharma A/S
  • Daiichi Sankyo
  • iCAD Inc
  • AB Sciences
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll